Postoperative outcomes after laparoscopic or open gastrectomy. A national cohort study of 10,343 patients.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
08 2021
Historique:
received: 18 01 2021
revised: 15 03 2021
accepted: 17 05 2021
pubmed: 4 6 2021
medline: 15 12 2021
entrez: 3 6 2021
Statut: ppublish

Résumé

Laparoscopy for gastric cancer has not been as popular compared with other digestive surgeries, with conflicting reports on outcomes. The aim of this study focuses on the surgical techniques comparing open and laparoscopy by assessing the morbi-mortality and long-term complications after gastrectomy. A retrospective study (2013-2018) was performed on a prospective national cohort (PMSI). All patients undergoing resection for gastric cancer with a partial gastrectomy (PG) or total gastrectomy (TG) were included. Overall morbidity at 90 post-operative days and long-term results were the main outcomes. The groups (open and laparoscopy) were compared using a propensity score and volume activity matching after stratification on resection type (TG or PG). A total of 10,343 patients were included. The overall 90-day mortality and morbidity were 7% and 45%, with reintervention required in 9.1%. High centre volume was associated with improved outcomes. There was no difference in population characteristics between groups after matching. An overall benefit for a laparoscopic approach after PG was found for morbidity (Open = 39.4% vs. Laparoscopy = 32.6%, p = 0.01), length of stay (Open = 14[10-21] vs. Laparoscopy = 11[8-17] days, p<0.0001). For TG, increased reintervention rate (Open = 10.8% vs. Laparoscopy = 14.5%, p = 0.04) and increased oesophageal stricture rate (HR = 2.54[1.67-3.85], p<0.001) were encountered after a laparoscopic approach. No benefit on mortality was found for laparoscopic approach in both type of resections after adjusted analysis. Laparoscopy is feasible for PG with a substantial benefit on morbidity and length of stay, however, laparoscopic TG should be performed with caution, with of higher rates of reintervention and oesophageal stricture.

Sections du résumé

BACKGROUND
Laparoscopy for gastric cancer has not been as popular compared with other digestive surgeries, with conflicting reports on outcomes. The aim of this study focuses on the surgical techniques comparing open and laparoscopy by assessing the morbi-mortality and long-term complications after gastrectomy.
METHODS
A retrospective study (2013-2018) was performed on a prospective national cohort (PMSI). All patients undergoing resection for gastric cancer with a partial gastrectomy (PG) or total gastrectomy (TG) were included. Overall morbidity at 90 post-operative days and long-term results were the main outcomes. The groups (open and laparoscopy) were compared using a propensity score and volume activity matching after stratification on resection type (TG or PG).
RESULTS
A total of 10,343 patients were included. The overall 90-day mortality and morbidity were 7% and 45%, with reintervention required in 9.1%. High centre volume was associated with improved outcomes. There was no difference in population characteristics between groups after matching. An overall benefit for a laparoscopic approach after PG was found for morbidity (Open = 39.4% vs. Laparoscopy = 32.6%, p = 0.01), length of stay (Open = 14[10-21] vs. Laparoscopy = 11[8-17] days, p<0.0001). For TG, increased reintervention rate (Open = 10.8% vs. Laparoscopy = 14.5%, p = 0.04) and increased oesophageal stricture rate (HR = 2.54[1.67-3.85], p<0.001) were encountered after a laparoscopic approach. No benefit on mortality was found for laparoscopic approach in both type of resections after adjusted analysis.
CONCLUSIONS
Laparoscopy is feasible for PG with a substantial benefit on morbidity and length of stay, however, laparoscopic TG should be performed with caution, with of higher rates of reintervention and oesophageal stricture.

Identifiants

pubmed: 34078568
pii: S0748-7983(21)00529-1
doi: 10.1016/j.ejso.2021.05.034
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1985-1995

Informations de copyright

Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest We certify that the authors have no conflict of interest to report.

Auteurs

Alexandre Challine (A)

Department of Digestive Surgery, APHP, Hôpital Cochin, Paris, France; Université de Paris, France; INSERM UMR 1138 Team 22, Centre de Recherche des Cordeliers, France.

Thibault Voron (T)

Department of Digestive Surgery, AP-HP, Hôpital, Saint Antoine, F-75012, Paris, France; Sorbonne Université, France.

Bertrand Dousset (B)

Department of Digestive Surgery, APHP, Hôpital Cochin, Paris, France; Université de Paris, France.

Ben Creavin (B)

Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

Sandrine Katsahian (S)

Université de Paris, France; INSERM UMR 1138 Team 22, Centre de Recherche des Cordeliers, France; Department of Biostatics, Hôpital Européen Georges Pompidou, APHP, Paris, France.

Yann Parc (Y)

Department of Digestive Surgery, AP-HP, Hôpital, Saint Antoine, F-75012, Paris, France; Sorbonne Université, France.

Andrea Lazzati (A)

Université de Paris, France; INSERM UMR 1138 Team 22, Centre de Recherche des Cordeliers, France; Department of Digestive Surgery, Centre Hospitalier Intercommunal de Créteil, Creteil, France.

Jérémie H Lefèvre (JH)

Department of Digestive Surgery, AP-HP, Hôpital, Saint Antoine, F-75012, Paris, France; Sorbonne Université, France. Electronic address: jeremie.lefevre@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH